Kyprolis and Tumor marker increased - a phase IV clinical study of FDA data

Summary:

Tumor marker increased is reported as a side effect among people who take Kyprolis (carfilzomib), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Revlimid,.

The phase IV clinical study analyzes which people have Tumor marker increased when taking Kyprolis. It is created by eHealthMe based on reports of 15,068 people who have side effects when taking Kyprolis from the FDA, and is updated regularly.

What is Kyprolis?

Kyprolis has active ingredients of carfilzomib. It is often used in multiple myeloma. eHealthMe is studying from 15,080 Kyprolis users. Check the latest studies of Kyprolis.

What is Tumor marker increased?

Tumor marker increased is found to be associated with 352 drugs and 388 conditions by eHealthMe. Check the latest studies of Tumor marker increased.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

15,068 people reported to have side effects when taking Kyprolis.
Among them, 11 people (0.07%) have Tumor marker increased.

Could Kyprolis cause Tumor marker increased?

Among these 11 people:

How long have people been on Kyprolis when they have Tumor marker increased? *

What is the gender of people who have Tumor marker increased when taking Kyprolis? *

female: 20 %
male: 80 %

What is the age of people who have Tumor marker increased when taking Kyprolis? *

What are other drugs people take besides Kyprolis? *

What are other side effects people have besides Tumor marker increased? *

Weakness: 3 people, 27.27%
Rashes (redness): 2 people, 18.18%
Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 2 people, 18.18%
Constipation: 2 people, 18.18%
Drug Ineffective: 2 people, 18.18%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 9.09%
Acute Kidney Failure: 1 person, 9.09%
Agitation (state of anxiety or nervous excitement): 1 person, 9.09%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 1 person, 9.09%
Anaemia (lack of blood): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Kyprolis and have Tumor marker increased?

- Check whether Tumor marker increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Kyprolis:

Kyprolis (15,080 reports)

Browse all side effects of Kyprolis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Tumor marker increased:

Tumor marker increased (352 drugs)

Browse all the conditions that are associated with Tumor marker increased:

Tumor marker increased (388 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on carfilzomib (the active ingredients of Kyprolis) and Kyprolis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.